Insider Transactions in Q4 2021 at Calithera Biosciences, Inc. (CALA)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 11
2021
|
Keith Orford Director |
SELL
Open market or private sale
|
Direct |
48,190
-42.17%
|
$0
$0.88 P/Share
|
|
Nov 10
2021
|
Keith Orford Director |
SELL
Open market or private sale
|
Direct |
30,000
-20.79%
|
$0
$0.86 P/Share
|
|
Nov 10
2021
|
Christopher Molineaux SR. VP, DEVELOPMENT |
BUY
Open market or private purchase
|
Indirect |
100,000
+15.22%
|
$0
$0.85 P/Share
|
|
Nov 10
2021
|
Jonathan G Drachman Director |
BUY
Open market or private purchase
|
Direct |
200,000
+50.0%
|
$0
$0.86 P/Share
|
|
Nov 10
2021
|
Susan Molineaux PRESIDENT & CEO |
BUY
Open market or private purchase
|
Indirect |
100,000
+15.22%
|
$0
$0.85 P/Share
|
|
Nov 09
2021
|
Keith Orford Director |
SELL
Open market or private sale
|
Direct |
51,810
-26.42%
|
$0
$0.84 P/Share
|
|
Nov 08
2021
|
Francesco Parlati SR. VP, RESEARCH |
SELL
Payment of exercise price or tax liability
|
Direct |
15,566
-8.68%
|
$0
$0.87 P/Share
|
|
Nov 08
2021
|
Emil Kuriakose CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,077
-4.25%
|
$0
$0.87 P/Share
|
|
Nov 08
2021
|
Stephanie Wong Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,566
-9.09%
|
$0
$0.87 P/Share
|
|
Nov 08
2021
|
Eric Sjogren SR. VP, DRUG DISCOVERY |
SELL
Payment of exercise price or tax liability
|
Direct |
15,566
-7.38%
|
$0
$0.87 P/Share
|
|
Nov 05
2021
|
Francesco Parlati SR. VP, RESEARCH |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+14.32%
|
-
|
|
Nov 05
2021
|
Emil Kuriakose CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+14.21%
|
-
|
|
Nov 05
2021
|
Sumita Ray Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+10.26%
|
-
|
|
Nov 05
2021
|
Stephanie Wong Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+14.9%
|
-
|
|
Nov 05
2021
|
Eric Sjogren SR. VP, DRUG DISCOVERY |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+12.45%
|
-
|
|
Nov 05
2021
|
Christopher Molineaux SR. VP, DEVELOPMENT |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+10.48%
|
-
|
|
Nov 05
2021
|
Keith Orford Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+13.27%
|
-
|
|
Oct 28
2021
|
Francesco Parlati SR. VP, RESEARCH |
SELL
Payment of exercise price or tax liability
|
Direct |
45,965
-23.52%
|
$45,965
$1.89 P/Share
|
|
Oct 28
2021
|
Stephanie Wong Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
45,965
-24.54%
|
$45,965
$1.89 P/Share
|
|
Oct 28
2021
|
Eric Sjogren SR. VP, DRUG DISCOVERY |
SELL
Payment of exercise price or tax liability
|
Direct |
45,965
-20.26%
|
$45,965
$1.89 P/Share
|
|
Oct 27
2021
|
Francesco Parlati SR. VP, RESEARCH |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+31.53%
|
-
|
|
Oct 27
2021
|
Sumita Ray Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,000
+27.91%
|
-
|
|
Oct 27
2021
|
Stephanie Wong Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+32.46%
|
-
|
|
Oct 27
2021
|
Christopher Molineaux SR. VP, DEVELOPMENT |
BUY
Grant, award, or other acquisition
|
Direct |
36,000
+28.46%
|
-
|
|
Oct 27
2021
|
Keith Orford Director |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+35.14%
|
-
|
|
Oct 27
2021
|
Eric Sjogren SR. VP, DRUG DISCOVERY |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+28.41%
|
-
|